AstraZeneca secured the rights to develop, produce and commercialize Merck & Co.'s experimental drug MK-1775, which is in midstage trials for ovarian cancer. The deal entitles Merck to $50 million upfront, potential milestone fees and sales royalties. "The compound has demonstrated encouraging clinical efficacy data, and we intend to study it in a range of cancer types where there is a high unmet medical need," said Susan Galbraith, head of AstraZeneca's oncology innovative medicines unit.

Related Summaries